Introduction
Results
The 89 Zr-DFO radiolabeling efficiency of Jurkat/CAR and human peripheral blood mononuclear cells (hPBMC)/CAR T-cells was 70%-79%, and cell radiolabeling activity was 98.1-103.6 kBq/10 6 cells. Cell viability after radiolabeling was >95%. Cell proliferation was not significantly different during the early period after radiolabeling, compared with unlabeled cells; however, the proliferative capacity decreased over time (day 7 after labeling). IL-2 or IFN-γ secretion was not significantly different between unlabeled and labeled CAR T-cells. PET/magnetic resonance imaging in the xenograft model showed that most of the 89 Zr-DFO-labeled Jurkat/CAR T-cells were distributed in the lung (24.4% ± 3.4%ID) and liver (22.9% ± 5.6%ID) by one hour after injection. The cells gradually migrated from the lung to the liver and spleen by day 1, and remained stable in these sites until day 7 (on day 7: lung 3.9% ± 0.3%ID, liver 36.4% ± 2.7%ID, spleen 1.4% ± 0.3%ID). No significant accumulation of labeled cells was identified in tumors. A similar pattern was observed in ex vivo biodistributions on day 7 (lung 3.0% ± 1.0%ID, liver 19.8% ± 2.2%ID, spleen 2.3% ± 1.7%ID). 89 Zr-DFO-labeled hPBMC/CAR T-cells showed a similar distribution, compared with Jurkat/CAR T-cells, on serial PET images. CAR T cell distribution was cross-confirmed by flow cytometry, Alu polymerase chain reaction, and immunohistochemistry. PLOS ONE | https://doi.org/10.1371/journal.pone.0223814 January 7, 2020 1 / 21 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Introduction
Given shifting cancer treatment paradigms, chimeric antigen receptor (CAR) T-cell immunotherapy has been developed very rapidly [1, 2] . CAR T-cells, which have been studied in the context of being used in immune regulatory cell therapies, harbor fusion proteins with the extracellular scFv domain of an antibody. These proteins recognize the characteristic antigen on the tumor cell surface and the intracellular costimulatory domain for T-cell activation. When CAR T-cells bind to the antigen on the surface of the tumor cell, a sequential costimulatory signal activates the T-cell and triggers the signaling pathway within the cell, thereby enabling the CAR T-cells to kill the tumor cell [3, 4] . Moreover, because of their tumor cell-killing activity, CAR T-cells act as a "living drug" that can proliferate in the body. They also have significantly longer action than conventional chemotherapeutics and antibody drugs [5] . CAR T-cell therapy has been shown to have dramatic anticancer effects, particularly in clinical trials for patients with hematological malignancies, such as refractory B-cell malignancies, after standard treatment [6] [7] [8] . Despite its successful use in patients with B-cell malignancies, there is a lack of substantive understanding of the actions of CAR T-cells in the human body with respect to the following: 1) the limited effect of CAR T-cells on solid tumors; 2) the trafficking and biodistribution of CAR T-cells; and 3) the targeting efficacy of CAR T-cells that are injected into a patient's body. To date, there are no available standardized methods for monitoring in vivo behaviors and targeting the efficacy of injected CAR T-cells. The most common (but limited) techniques used to identify CAR T-cells in the body are flow cytometry, biopsy/immunohistochemistry (IHC), enzyme-linked immunosorbent (ELISpot), and polymerase chain reaction (PCR) [9] [10] [11] [12] . Unfortunately, none of these can monitor CAR T-cells within a live body. To optimize the efficacy of CAR T-cell immunotherapy, and to predict potential toxicities, it is necessary to develop a noninvasive imaging system that can enable the monitoring of CAR T-cell trafficking in a real-time manner. Image-based data provides a great deal of information concerning actual tracking, targeting patterns, real-time distributions, and in vivo maintenance for CAR T-cell therapies.
Additionally, the FDA Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products (updated 11/2013) acknowledged that the fate of investigational cell therapy, after in vivo administration, is important for characterizing the product's activity and safety information. To determine the distribution of cells after administration, imaging methods such as the use of radioisotope-labeled cells, genetically engineered cells (e.g., green fluorescent protein expression), and nanoparticle-labeled cells (e.g., iron-dextran nanoparticles) are recommended. Unlike conventional drugs, cell therapies must acquire data through in vitro experiments to determine their pharmacological activities or any unrecognized toxicity. Therefore, animal models are generally recommended for evaluating cell therapies because basic information on the initial behavior, organ distribution, and targeting in the body after cell therapy are important. Nuclear medical imaging is a valid method that enables real-time monitoring of cells in the body.
Positron emission tomography (PET) is a method of diagnostic imaging that can evaluate metabolic activities in the body; injection of a radioactive tracer enables this nuclear medicine functional imaging technique. PET is a unique and important tool for the tracking of cells in preclinical and clinical studies [13, 14] . It can be used for translational research, i.e. moving from preclinical to clinical studies, as this technology is highly sensitive and has excellent spatial resolution. There are two ways to label cells for imaging: direct and indirect labeling. This study was designed to monitor CAR T-cells using direct labeling. Direct labeling of cells immediately marks the cells with a radioisotope through covalent bond conjugation. Cell migration and distribution can be monitored immediately after cell injection. Herein, we establish a method of direct labeling for CAR T-cells. Since CAR T-cells can be manipulated ex vivo, it is possible to track the behavior and the distribution of small numbers of radiolabeled cells after in vitro labeling. 89 Zr has a long physical half-life (78.4 hours) and is therefore suitable for tracking the behavior of CAR T-cells in the body. In previous studies, cells for imaging were directly labeled using isotopes conjugated with 89 Zr-oxine or DFO moiety. [15] [16] [17] [18] . Recently, Weist et al. proposed that 89 Zr-oxine would be a clinically translatable method for real-time evaluation of cell therapies, especially that using CAR T-cells [19] . However, Bansal et al. [16] reported that the 89 Zr-DFO labeling strategy was superior to that of 89 Zr-oxine, with increased cell stability and viability. Based on existing preclinical applications, this study aimed to assess the feasibility of real-time trafficking of 89 Zr-DFO-labeled CAR T-cells using PET imaging.
Materials and methods

Study design
For the exploration of CAR-T cell trafficking by PET imaging, we first performed the experiments with cultured Jurkat cells (immortalized T lymphocyte cell line), and subsequently we used human peripheral blood mononuclear cells (hPBMC). After construction of lentiviral CD19 targeting CAR vectors, we prepared CAR-expressing Jurkat (Jurkat/CAR) T-cells and CAR T-cells from hPBMC (hPBMC/CAR T-cells). All the cells were then radiolabeled with 89 Zr-DFO. The in vitro viability, proliferation ability, and function of the 89 Zr-DFO-labeled cells were evaluated. 89 Zr-DFO-labeled Jurkat/CAR T-cells were intravenously injected into mice xenograft models with bilateral CD19 positive and negative tumors. We carried out serial imaging studies for seven days of cell trafficking in vivo using a PET/magnetic resonance (MR) scanner. The imaging data were compared with those of the ex vivo experiments performed with unlabeled Jurkat/CAR T-cells. Then, similar imaging studies were carried out using 89 Zr-DFO-labeled hPBMC/CAR T-cells. The animal study scheme is shown in Fig 1. The research protocol of this preclinical experimental study with animals was approved by the Institutional Animal Care and Use Committee of the Asan Institute for Life Science (registration no. 2017-12-085). Mice were maintained in accordance with the Institutional Animal Care and Use Committee guidelines of the Asan Institute for Life Science. For the hPBMC preparation, blood samples were drawn from healthy volunteer donors, who had given their written informed consent, according to the protocol approved by the Research Institute of the National Cancer Center following the Institutional Review Board (NCC2018-0030 and NCC2015-0312).
Cell culture and hPBMC preparation. Raji (CD19 positive cell line, ATCC), K562 (CD19 negative cell line, ATCC), and Jurkat (ATCC) were cultured in RPMI 1640 containing FBS (10%, GenDEPOT), L-glutamine (2 mmol/L, Gibco) and antibiotic-antimycotic (100x, Gibco). The hPBMCs in the blood samples were isolated by using Ficoll-Paque (GE Healthcare) and cultured as above; we additionally treated hIL-2 (200 U/ml, R&D systems).
Construction of a lentiviral vector containing CD19-specific CAR.
To construct a lentiviral vector encoding CAR specific to CD19, we generated the EF1α promoter-driven lentiviral expression vector, pLECE3. The pLECE3 was constructed by replacing the U6 promoter of pLentiLox3.7 with the EF1α promoter, together with a few additional cloning sites. The 19BBz consists of an anti-CD19 scFv, a CD8 Hinge, a CD8 transmembrane, a 4-1BB, and a CD3 z domain, which are identical with the Novartis Kymriah product. DNA products of 19BBz domain were amplified by PCR (19BBz; 5'-GATCCgccaccATGGCCTTA CCAGTGA-3' and 5'-GTTAACttaGCGAGGGGGCAGGGCCTGCAT-3'). The PCR product was then subcloned into a pGEM-T-easy vector (Promega, USA). The 19BBz was inserted into the pLECE3 at the BamHI/HpaI site, under the EF1a promoter (Fig 2A) .
Transfection and lentivirus packaging. The lentiviral vectors were transfected into the 293T cells with Lipofectamine 30001 (Thermo Fisher Scientific), following the manufacturer's protocol. Briefly, 7 × 10 6 293T cells (ATCC) were plated in 150 mm petri dishes. The cells were treated with a lipofectamine reagent, viral vectors, and packaging DNA. For high-titer lentiviral purification, cellular supernatants were collected and filtered through a 45 μm pore filter unit (Sartorius AG, Germany) at 48 hours post transfection, and purified using ultracentrifugation.
Transduction of lentivirus into Jurkat T-cells and hPBMCs. We plated 4 × 10 5 Jurkat T-cells (ATCC, TIB-152) one day before transduction. The next day, the cells were infected with the lentiviruses (MOI 1000), with polybrene (8 μl/ml, Merk, Germany) added to increase the efficiency of transduction. Then, a 90-minute spin infection was performed (800 × g). We sorted transduced Jurkat T-cells that expressed 19BBz 72 hours later using FACS Aria (BD Biosciences, USA). Briefly, the biotin-SP-conjugated goat antimouse IgG F(ab')2 fragmentspecific antibody was used as a primary antibody to capture the CAR, and the PerCP/Cy5.5 Streptavidin antibody (Biolegend, USA) was used as a secondary antibody. The CD19 expression levels are shown in Fig 2B. The sorted cells were cultured again to establish stable Jurkat/ CAR T-cell lines. On the other hand, CD19 hPBMC CAR T-cells were generated by transduction of hPBMCs with lentivirus prepared as described elsewhere [7] .
Synthesis of the 89 Zr-DFO complex for cell labeling. 89 ZrCl 4 was prepared from the 89 Zr-oxalate (Perkin Elmer). 89 Zr-DFO complex was synthesized using 2.8 nmol of DFO and 62.9 ± 29.6 MBq of 89 ZrCl 4 and analyzed with a slight modification of the previously reported method [16] . We only changed the reagent of neutralization from KOH to NaOH, and the incubation time from one hour to overnight, to increase the chelation efficiency to over 90%. 89 Zr-DFO. Cell labeling with 89 Zr-DFO was performed with a slight modification of the previously described method [15] . Briefly, the Jurkat/CAR Tcells were counted, harvested and washed once with HBSS buffer (pH 7.5). Then, 185 kBq/ 100 μl HBSS buffer of 89 Zr-DFO was added to each glass tube with 5 × 10 6 cells in 500 μl HBSS buffer and incubated in a thermomixer at 37˚C for 30 minutes (Eppendorf, Germany) with gentle shaking. After incubation, we added 1 ml of cold HBSS buffer, and the solution was centrifuged at 1200 rpm for five minutes at 4˚C in order to separate the supernatant. The supernatant was collected in a new tube, and we repeated this washing process three times. The final cell labeling efficiency was calculated as follows: labeling efficiency (%) = [cell activity (cpm)/ {cell activity (cpm) + supernatant activity (cpm)}] × 100. CAR T-cells from the hPBMC were labeled using the same procedure as with the Jurkat /CAR T-cells, but 89 Zr-DFO 74 kBq / 100 μl HBSS buffer was added to each tube.
Labeling of CAR T-cells with
Cell viability and proliferative activity of 89 Zr-DFO-labeled cells. To investigate the cell viability and proliferation rates, 89 Zr-DFO-labeled and unlabeled cells were seeded, 2 × 10 45 × 10 5 cells/well in six well plates containing 5 ml of culture medium. After seeding, the cell viability was assessed using trypan blue exclusion assay at one hour, one day, three days, and seven days. Simultaneously, the cell proliferation rate was compared with that of the unlabeled cells. The seeded cells were maintained at 37˚C in a 5% CO 2 incubator. The unlabeled cells served as controls. 
Function test for 89 Zr-DFO-labeled cells.
To determine the function of the 89 Zr-DFOlabeled Jurkat/CAR T-cells, we evaluated the target cell-specific cytokine IL-2 production ability with CD19 positive Raji cells (Burkitt lymphoma, ATCC, CCL-86) and CD19 negative K562 cells (chronic myelogenous leukemia, ATCC, CCL-243) as target cells. We then compared the results from the 89 Zr-DFO-labeled cells with the results obtained from the unlabeled Jurkat/CAR T-cells. For IL-2 secretion assay, 89 Zr-DFO-labeled cells were seeded, 4 × 10 4 cells/well in six well plates, and were cultured for 12 or 36 hours at a 4:1 ratio [effector cells: target cells (Raji or K562 cells)]. Human IL-2 ELISA assay (RayBiotech, GA, USA) was performed according to the manufacturer's instructions. To observe the function of the 89 Zr-DFO-labeled hPBMC CAR T-cells, we additionally performed IFN-γ release assay (RayBiotech, GA, USA) according to the manufacturer's instructions.
Animal model establishment. To develop a mouse xenograft model, immunodeficient NSG mice (female, 5-6 weeks old, 20-22 g) from Jackson Laboratory (USA) were used. To compare tumor specific targeting of CAR T-cells, we used two cell lines, Raji and K562, which presented different CD19 protein expression (S2 File). 5 × 10 6 of the Raji cells were injected into the left flank, and 5 × 10 5 of the K562 cells were injected into the right flank, of the same mouse. The mice were maintained in accordance with the Institutional Animal Care and Use Committee guidelines of the Asan Institute for Life Science. Over the following five to seven days we selected six mice out of 12 for PET/MR imaging if the tumors reached a volume of 50 to 100 mm 3 . Mice with tumor growth failure, or inappropriate tumor size, were excluded. Tumor volume was measured three times per week and calculated as length × width × height × π/6 (mm 3 ).
Animal PET-MR imaging and image analysis. PET-MRI fusion imaging was performed using nanoScan PET/MRI (1T, Mediso, Hungary). After careful review of previous studies [16, 18, 20] , we obtained the images through the following process. 89 Zr-DFO-labeled Jurkat/ CAR T-cells (n, median: 4.1 × 10 6 , range: 3.1-5.4 × 10 6 ; radioactivity, median: 907 kBq, range: 481-1221 kBq) were slowly injected intravenously through a tail vein of each mouse (n = 4) using a 26 G syringe. Before PET image acquisition, the mice were kept under anesthesia (1.5% isoflurane in 100% O 2 gas). Imaging was performed on day 0 (one hour after the injection) and again on days 1, 2, 5, 6 and 7. The T1 weighted with gradient-echo three-dimensional (3D) sequence (TR = 25 ms, TEeff = 3.4, FOV = 64 mm, matrix = 128 × 128) MR images were acquired, followed by static PET images for ten minutes (days 0 and 1), 20 minutes (day 2), or 30 minutes (days 5, 6 and 7) in a 1:5 coincidence mode and a single field of view within the MRI range. Body temperature was controlled by heated air directed onto the animal bedding (Multicell, Mediso, Hungry), and a pressure-sensitive pad was used for respiratory triggering. In addition, we also obtained PET/MR images of the mice after injecting the 89 Zr-DFO-labeled hPBMC CAR T-cells (n = 2) through a similar process, as above.
PET images were reconstructed using Tera-Tomo 3D, in full detector mode: with all the corrections on, high regularization and eight iterations. A 3D volume of interest (VOI) was applied to organs and tumors on the reconstructed PET and MR images using the InterView Fusion software package (Mediso, Hungary) and quantitative analysis procedures. Then, percentage of injected doses (%ID; percentage of radioactivity in each organ to injected radioactivity) were calculated. VOIs, with a fixed 2 mm diameter sphere, were also drawn for the tumors (Raji and K562), brains, hearts (left ventricles), lungs, livers, kidneys, spleens, and bones (femurs), and they were analyzed using the following formula: standardized uptake value (SUV) = (radioactivity in the VOI with the unit of Bq/cc × body weight) divided by injected radioactivity.
Ex vivo biodistribution study. Immediately after the PET-MR image acquisition on day 7, the 89 Zr-DFO-labeled Jurkat/CAR T-cell injected mice (n = 4) were sacrificed by cardiac puncture under anesthesia, to reduce pain without affecting the experimental results. Their organs (brain, heart, lung, liver, spleen, kidney, stomach, intestine, bone, muscle, etc.) and tumors were excised, weighed, and counted using a gamma-counter for five minutes. The %ID values were obtained, after normalizing to the weight of each organ.
Flow cytometry analysis. To validate the biodistribution of Jurkat/CAR T-cells after injection, we performed ex vivo immunostaining of organs. The mouse organs (liver, spleen) were harvested on day 3 after injection of unlabeled Jurkat/CAR T-cells (2 × 10 7 / 200 μl) into the NSG mice with tumors, via their tail veins (n = 2). The tissues were ground using a gentleMACS™ Dissociator (Miltenyi Biotec, Germany) in accordance with the supplier's protocol. A mouse cell depletion kit (Miltenyi Biotec, Germany) was used to separate the Jurkat/CAR T-cells from the mouse cells. After counting the live cells, the human T-cell isolation kit (Miltenyi Biotec, Germany) was used, according to the supplier's protocol. Red blood cells were removed using an RBC lysing buffer (Sigma Aldrich, MO) for one minute, followed by washing and re-suspension in 1x HBSS containing 1% FBS. The separated cells were used with PE-conjugated anti-CD3. The analysis staining process was the same as that used in vitro. Data were acquired from the stained cells using BD FACS CantoII flow cytometry (BD Biosciences). The results were evaluated with FlowJo software (Treestar Inc., Ashland, OR).
Preparation of genomic DNA and Alu PCR analysis. To validate the biodistribution of Jurkat/CAR T-cells after injection, we also performed PCR analysis of ex vivo tissue (n = 3). At three days after injection of 2 × 10 7 of Jurkat/CAR T-cells into the mice through their tail veins, the mice were sacrificed and brain, heart, lung, liver, spleen, and kidney samples were collected. For the Alu PCR assay to detect injected human cells, genomic DNA was extracted from the tissue samples using the QIAamp1 (Qiagen, Germany) according to the manufacturer's protocol. The primers used in this study were as follows: for human Alu, 5'-CACCTG TAATCCCAGCACTTT-3' (forward primer) and 5'-CCCAGGCTGGAGTGCAGT-3' (reverse primer). Real-time PCR was performed using SYBR1 Green Realtime PCR Master Mix (TOYOBO, Japan) and the ABI 7500 Fast Real-Time PCR System (Applied Biosystems, CA, USA), according to the manufacturers' instructions. The PCR experimental conditions were: 95˚C for ten minutes, followed by 40 cycles at 95˚C for 15 seconds and 60˚C for one minute. This was followed by melting curve cycles at 95˚C for 15 seconds, at 60˚C for one minute, and finally at 95˚C for 15 seconds. We used concentrations that were one, 5, and 25 dilutions based on 10 6 cells of Jurkat/CAR T-cells expressing CD19 as a standard. The results indicated the amount of Alu expression, based on the standard. Immunohistochemistry analysis. IHC analysis was performed as previously described [20] . The mice were sacrificed on day 3 (n = 3) or day 7 (n = 2) after Jurkat/CAR or hPBMC CAR T-cells were injected into the tumor-bearing mice. With the day 3 group, after injection of Jurkat/CAR T-cells, the liver, spleen, and tumors were harvested and fixed within paraffin blocks for IHC staining. The slides were stained with an anti-CD3 antibody (Abcam, UK) with the Dako REAL™ EnVision™ Detection System (Agilent Technologies, Inc., CA, USA) and were counter-stained with hematoxylin.
Statistical analysis
Data are shown as mean ± SD unless otherwise stated. A value of p < 0.05 was considered to be statistically significant. The Kruskal-Wallis test was used to determine the differences between time points after 89 Zr-DFO labeling, and the Mann-Whitney test was used to determine the differences between 89 Zr-DFO-labeled and unlabeled cells. Statistical analyzes were performed by GraphPad Prism (GraphPad Software, CA, USA).
Results
Labeling efficiency, viability and proliferative ability of 89 Zr-DFO-labeled Jurkat/CAR T-cells and CAR T-cells
The 89 Zr-DFO labeling efficiency of Jurkat/CAR T-cells was 72.8% ± 11.0% at 185 kBq ( Fig  3A) . Cell viability after 89 Zr-DFO labeling was 95.2% ± 1.2%, similar to the levels obtained before labeling. The concentration of radioactivity for the Jurkat/CAR T-cells was 103.6 kBq/ 10 6 cells. The labeling of hPBMC CAR T-cells proceeded to 74 kBq. The 89 Zr-DFO labeling efficiency was similar to that of the Jurkat/CAR T-cells ( Fig 3A) . The 89 Zr-DFO-labeled hPBMC CAR T-cells showed a radioactivity concentration of 98.1 kBq/10 6 cells.
We checked cell viability and cell proliferative ability at one hour, one day, three days and seven days after 89 Zr-DFO cell labeling. There was no statistically significant difference in cell viability, although viability decreased over time after cell labeling (p = 0.24, 1 hour: 92.6% ± 3.1%, day 1: 89.4% ± 4.4%, day 3: 85.7% ± 8.1%, day 7: 89.0% ± 4.9%, respectively) ( Fig 3B) . However, the 89 Zr-DFO-labeled cells showed decreased proliferative ability in a time-dependent manner (Fig 3C) . At one hour after cell labeling, cell proliferation ability was not significantly changed, compared with that of the unlabeled cells (p = 0.25). However, cell proliferation significantly decreased over time (1 hour: 1.28 ± 0.44, day 1: 0.69 ± 0.13, day 3: 0.54 ± 0.15, and day 7: 0.49 ± 0.32, respectively).
Functional test for 89 Zr-DFO-labeled Jurkat/CAR T-cells or CAR T-cells
CAR T-cell function was assessed by target cell-specific cytokine IL-2 production ability at 12 and 36 hours after cell labeling. Both 89 Zr-DFO-labeled and unlabeled Jurkat/CAR T-cells induced IL-2 release in the positive target cells (Raji) at similar levels (74.1 vs 76.5 ng/ml at 12 hours, p = 0.99; 86.4 vs 87.1 ng/ml at 36 hours, p = 0.85) ( Fig 4A) . IL-2 was not released in the negative target cells (K562), which did not react with the Jurkat/CAR T-cells.
The IL-2 secretion of hPBMC 89 Zr-DFO-labeled CAR T-cells was also similar to that observed of the unlabeled cells ( Fig 4B) . When hPBMC CAR T-cells were added to Raji cells expressing the targeted CD19 cells, the secretion of IFN-γ involved in cell cytotoxicity was maintained after 89 Zr-DFO labeling (69.3 vs 71.6 ng/ml, p = 0.67) ( Fig 4C) .
Trafficking of 89 Zr-DFO-labeled Jurkat/CAR T-cells with PET/MR imaging
After injection of 89 Zr-DFO-labeled Jurkat/CAR T-cells through the tail veins of the mice, we used PET/MR imaging for noninvasive real-time tracking of the injected cells in vivo. The Jurkat/CAR T-cells were initially located in the lungs, then redistributed to the liver and spleen ( Fig 5A) . In more detail, the injected 89 Zr-DFO-labeled Jurkat/CAR T-cells were found mainly in the lung (24.4% ± 3.4%ID) and liver (22.9% ± 5.6%ID) during the first hour. Over time, the CAR T-cells gradually migrated from the lungs and accumulated mainly in the liver, with some in the spleen (Fig 5B) . However, radioactivity accumulation was not evident in either CD19-positive Raji or CD19-negative K562 tumors. The detailed quantitative values of the PET images, analyzed by SUV, are shown in Table 1 . Immediately after PET/MR imaging on day 7, the mice were sacrificed; their organs and tumors were then isolated to measure the radioactivity of injected cells ex vivo. The biodistribution data measured ex vivo on day 7 showed similar patterns of distribution to those assessed by the PET images, as shown in Fig  5C and Table 2. PET/MR imaging with 89 Zr-DFO-labeled CAR T-cells from hPBMC also showed similar biodistribution of cells after tail vein injection. We did not observe increased radioactivity in ⁸⁹Zr-DFO-labeled CAR T-cell PET the tumors, which would have suggested CAR T-cell homing (Fig 6) . The detailed quantitative values analyzed by SUV are shown in Table 3 .
Flow cytometry, Alu PCR and immunohistochemistry for the ex vivo organ study
We evaluated the biodistribution of unlabeled Jurkat/CAR T-cells after injection using nonimaging methods, for comparison with the evaluation using the imaging method. For flow cytometry, the liver and spleen tissue samples from mice were separated into single cells. After the initial separation, an average number of 3.05 × 10 7 and 1.67 × 10 6 cells per mouse were harvested. After depletion of mouse liver cells, an average of 4.74 × 10 4 cells was obtained after using a human T-cell isolation kit. In contrast with the negative control stained with isoform antibody, CD3 expressing CAR T-cells were distributed in 95.7% of the spleen and 60.3% of the liver (Fig 7A) .
Organ distributions of Jurkat/CAR T-cells were confirmed through Alu PCR. The blood, heart, lung, liver, spleen and kidney were sampled, and CD19 CAR T-cells were distributed in all six organs. The relative Alu expression was determined by measuring the blood, and the fold was as follows: brain (15.1 ± 5.8), heart (6.2 ± 7.2), lung (38.5 ± 34.8), liver (212.2 ± 225.4), spleen (70.3 ± 9.4), kidney (9.4 ± 6.4) and gut (17.5 ± 8.9) ( Fig 7B) .
Immunohistochemical staining of liver and spleen tissues with CD3 confirmed the presence of Jurkat/CAR T-cells in the liver and spleen, in contrast with the control tissue from mice not injected with Jurkat/CAR T-cells ( Fig 8A) . Immunohistochemical staining of Raji and K562 tumors of the day 3 group with CD3 showed barely-visible stained cells in the periphery of the tumors. In the day 7 group, hPBMC CAR T-cells showed proliferation throughout Raji tumors; however, Jurkat/CAR T-cells were not visualized ( Fig 8B) . No K562 tumors were stained with CD3 antibody.
Discussion
In this study, in vivo CAR T-cell trafficking was feasible for seven days after intravenous injection by 89 Zr-DFO labeling and PET/MR images. The CAR T-cells initially reached the lungs and gradually migrated to the liver by day 1, where they remained for the rest of the experimental period. Migration to the spleen was also evident and showed high SUV on PET/MR images, although %ID was relatively low, and the spleen is small in immunocompromised NSG mice. The organ distribution of 89 Zr-DFO-labeled cells, quantitatively assessed by PET/ MR images, was confirmed with an ex vivo biodistribution study in which we analyzed the radioactivity of each organ harvested from the mice on day 7. This pattern of distribution was observed in both 89 Zr-DFO labeling of Jurkat/CAR T-cells and CAR T-cells from human peripheral blood. Although we did not perform control in vivo imaging, biodistribution of possible free form of radiotracer, such as 89 Zr-DFO or 89 Zr-chloride, is different to that of 89 Zr-DFO labelled CAR T-cells shown in this study. The distribution of cells after injection of unlabeled Jurkat/CAR T-cells was also confirmed by flow cytometry, Alu PCR, and IHC with isolated tissues from the sacrificed mice, on day 3. We could reliably and noninvasively track the distribution after cell administration using 89 Zr-DFO labeling of CAR T-cells and PET/MR imaging, as suggested by FDA guidance. In quantitative analysis of organ distribution of cell populations, previous studies with radioisotope labeling had a lack of specific organ distribution data because of the difficulties in gathering anatomical information with PET imaging alone. The current study was performed using a hybrid imaging system. Here PET and MR imaging allowed organ-specific detection of the cell signal, together with structural information. The quantitative nature of PET imaging allows for longitudinal studies that provide information on relative levels of CAR T-cells at both the site of disease and potential off-target sites of accumulation. Monitoring the locations and potential secondary sites involved in CAR Tcell trafficking enables us to characterize the activity of administered cells and the safety profile. 89 Zr-DFO was used for labeling CAR T-cells in this study, instead of 89 Zr-oxine complex, which was used by Weist et al. [19] , because it has more stable covalent binding between the DFO and cell surface protein [16] . With 89 Zr-DFO labeling of human immune cells, radioactivity concentrations of radioisotope-labeled cells of up to 0.5 MBq/10 6 cells were executed without an unfavorable effect on cellular viability, and cell efflux studies showed high radiolabel stability, with virtually no loss of tracer, for up to seven days [16] . Whereas a significant amount of 89 Zr-oxine can efflux from various kinds of cell, there is potential uptake of a small amount of free 89 Zr released from cells into the bones or kidneys, as shown in the report by Table 1 
. Quantitative analyses of 89 Zr-DFO-labeled Jurkat/CAR T-cells on PET images with SUV (mean ± SD, n = 4).
Tissues
Day 0 Weist et al. [19] . In our PET images of 89 Zr-DFO-labeled cells, less radioactivity accumulated in the bones and kidneys until seven days after injection, compared with the results reported using 89 Zr-oxine labeled cells. Furthermore, decay corrected injected activity was maintained on serial PET images (98.9 ± 8.3%), without significant loss of activity from the body. These findings suggest stable cell labeling by 89 Zr-DFO in vivo, as demonstrated in other studies. The cell viability and functionality, such as cytokine production, were not affected by labeling CAR T-cells with 89 Zr-DFO at radioactivity cell concentration of 98 kBq/10 6 cells. However, proliferation ability was slightly decreased over the next several days compared with that of unlabeled cells. It is important to consider the effect of the radiation dose on cells of hematopoietic origin, which are radiation sensitive. In particular, 89 Zr has high-energy gamma emissions of 908.97 keV, which may limit the radioactive dose; furthermore, the radiolabeling procedure is potentially cytotoxic. Therefore, we reduced the dose of 89 Zr-DFO, when labeling CAR T-cells from hPBMC, to 74 kBq/10 6 cells, compared with 185 kBq/10 6 cells in the labeling of Jurkat/CAR, after careful dose optimization because of hPBMC sensitivity.
The distribution pattern of CAR T-cells in this study was similar to that of previous studies. Following intravenous administration, human T-cells migrated in a manner similar to that reported in humans, but penetrated poorly into established tumors. Following intravenous administration, human T-cells initially reached the lungs, where they remained for more than four hours. After that, the T-cells redistributed to the liver, spleen, and lymph nodes [20] . This pattern was seen using all T-cell populations tested, regardless of tumor status or transgene cargo, and closely mimicked patterns of migration seen in human (via infusion) [21] [22] [23] or murine T-cell [24, 25] recipients. According to Charoenphun et al., 89 Zr-oxine labeled myeloma cells were injected intravenously and were found within the lungs at 30 minutes after injection, but migrated to the liver and spleen on day 1. This distribution continued until day 7 [26] . Similar distributions of 89 Zr -oxine labeled dendritic cells were observed by Sato et al. [18] . Weist et al. also found that the highest CAR T-cell activity was in the spleen, followed by the liver [19] . In these studies, lung activity was significantly lower on day 7 than the activity in the liver or spleen. In contrast, Bansal et al. found that mesenchymal stem cells exhibited persistently high activity in lung images, up to day 7, and their biodistribution study also showed the highest activity in the lung (approximately 50%ID), followed by the liver (approximately 25%ID) [16] . It has been suggested that the slow migration of transferred T-cells through the lungs may be due to low pulmonary circulatory pressure, coupled with the narrowing of capillaries during expiration [23] . Importantly, activated T-cells cross the pulmonary circulation with reduced intravascular velocity, compared with that of their inactivated or naive counterparts [27, 28] . This delay may, in part reflect an enhanced interaction between highaffinity state LFA-1 (T-cells) and ICAM-1 (endothelium) [27] . Delayed clearance of activated T-cells during their first pass through the lungs may be highly related with pulmonary toxicity that can occur following infusion of CAR T-cells. In one published incident, fatal adult respiratory distress syndrome occurred rapidly following infusion of > 10 10 T-cells, targeted against ErbB2 using a trastuzumab scFv coupled to a fused CD28/4-1BB/CD3z endoplasmic domain [29] . In this study, T-cell migration to the target tumor was not observed on PET images, unlike in the reports by Sato et al. and Weist et al. It was disappointing to observe that only a minority of intravenously administered CAR T-cells migrated to tumor deposits, even though we used CD19 CAR T-cells with proven efficacy in animals and humans. There are several potential causes of this phenomenon. We used Jurkat/CAR T-cells in this study, which are leukemia cells and not true T-cells. Although Jurkat cells were used for convenience in this experiment, their actual biological behavior may be different from normal T-cells. Second, the solid subcutaneous tumor xenograft model used in this study was a different tumor environment from that of human acute lymphocytic leukemia of the blood, for which CD19-CAR T-cells have been shown to have a dramatic therapeutic effect. Also, the differences in the antigen-presenting status of the tumor, tumor microenvironment etc. between the xenograft model generated from Raji cells and those of previous studies by Sato et al. (B16 murine melanoma cells [18] ) and Weist et al. (prostate cancer PC3-overexpressed cells [19] ) may have affected the accumulation of CAR-T-cells within tumor tissue [30] . Third, detection of cell trafficking by imaging has important limitations. Cell trafficking may not be detectable via PET imaging when small amounts of T-cells, below detectable limits, are injected. Furthermore, after homing to the tumor, activated CAR T-cells can proliferate and dilute the labeling signal. In our IHC & PET imaging data, hPBMC CAR T-cells showed proliferation within Raji tumor tissues after CD19 targeting ( Fig 8B) ; however, there are rare PET imaging signals in tumors.
There are several limitations to this study. First, we did not show a therapeutic effect for CAR T-cells because our experiments were conducted mainly with Jurkat/CAR T-cells instead of hPBMC CAR T-cells. Limited imaging experiments were possible using hPBMC CAR Tcells and only two mice. Second, the biodistribution study was only performed using direct cell labeling strategies. The direct cell labeling method cannot visualize cell proliferation after homing to the target tumor [31] . Third, we did not perform a control in vivo distribution study with 89 Zr-DFO or free form of 89 Zr, since this study was to explore the feasibility and we tried to use a minimum number of mice. To date, several previous in vivo biodistribution imaging studies have been well performed and are comparable with ours [15] , in which the biodistribution patterns of various forms of 89 Zr, including 89 Zr-DFO, were very different from those of the 89 Zr-DFO labelled cells. Therefore, we think that the PET/MR image results in this study reflect the biodistribution of the 89 Zr-DFO labelled CAR T-cells.
In this study, 89 Zr-DFO labeling CAR T-cell direct imaging had great advantages in enabling observation of the initial behavior of the injected cells, and in the whole-body distribution in real-time, with very low background activities, which, in principle, are not present in other host tissues or cells. This direct labeling did not involve genetic manipulation of the therapeutic cells and, therefore, it was a simple way to trace initial injected CAR T-cells.
Further studies that use both direct and indirect labeling strategies, where reporter genes are inserted in the vector, should be carried out using hPBMC CAR T-cells.
Conclusions
With 89 Zr-DFO labeling of CAR T-cell, real-time in vivo cell trafficking was feasible through PET imaging, after administration of these cells to the body. Thus, 89 Zr-DFO-labeled CAR Tcell PET imaging can be used to investigate the cell kinetics, in vivo cell biodistribution, and safety profile of CAR T-cell therapies that are developed. 
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